| Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of … A Sartore-Bianchi, L Trusolino, C Martino, K Bencardino, S Lonardi, ... The Lancet Oncology 17 (6), 738-746, 2016 | 942 | 2016 |
| Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1) A Drilon, S Siena, SHI Ou, M Patel, MJ Ahn, J Lee, TM Bauer, AF Farago, ... Cancer discovery 7 (4), 400-409, 2017 | 769 | 2017 |
| Sensitivity to entrectinib associated with a novel LMNA-NTRK1 gene fusion in metastatic colorectal cancer A Sartore-Bianchi, E Ardini, R Bosotti, A Amatu, E Valtorta, A Somaschini, ... Journal of the National Cancer Institute 108 (1), djv306, 2016 | 150 | 2016 |
| Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: Combined results from two phase I trials (ALKA-372-001 and STARTRK-1) Cancer … A Drilon, S Siena, SI Ou, M Patel, MJ Ahn, J Lee, TM Bauer, AF Farago, ... Published by S. Karger AG, Basel www. karger. com/cro Gupta et al.: A …, 2019 | 131 | 2019 |
| Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies G Mauri, EG Pizzutilo, A Amatu, K Bencardino, L Palmeri, EF Bonazzina, ... Cancer treatment reviews 73, 41-53, 2019 | 82 | 2019 |
| Regulatory cytokine gene polymorphisms and risk of colorectal carcinoma A Crivello, A Giacalone, M Vaglica, L Scola, GI Forte, MC Macaluso, ... Annals of the New York Academy of Sciences 1089 (1), 98-103, 2006 | 66 | 2006 |
| Regulatory cytokine gene polymorphisms and risk of colorectal carcinoma A Crivello, A Giacalone, M Vaglica, L Scola, GI Forte, MC Macaluso, ... Annals of the New York Academy of Sciences 1089 (1), 98-103, 2006 | 66 | 2006 |
| Regulatory cytokine gene polymorphisms and risk of colorectal carcinoma A Crivello, A Giacalone, M Vaglica, L Scola, GI Forte, MC Macaluso, ... Annals of the New York Academy of Sciences 1089 (1), 98-103, 2006 | 66 | 2006 |
| Cisplatin and gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site: results of an Italian multicenter, randomized, phase II … S Palmeri, V Lorusso, L Palmeri, M Vaglica, C Porta, R Nortilli, F Ferraú, ... Cancer 107 (12), 2898-2905, 2006 | 65 | 2006 |
| Phase 1 open label, dose escalation study of RXDX101, an oral pan-trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations. FG De Braud, L Pilla, M Niger, S Damian, B Bardazza, A Martinetti, ... Journal of Clinical Oncology 32 (15_suppl), 2502-2502, 2014 | 50 | 2014 |
| Alka-372-001: First-in-human, phase I study of entrectinib–an oral pan-trk, ROS1, and ALK inhibitor–in patients with advanced solid tumors with relevant molecular alterations. FG De Braud, M Niger, S Damian, B Bardazza, A Martinetti, G Pelosi, ... Journal of Clinical Oncology 33 (15_suppl), 2517-2517, 2015 | 47 | 2015 |
| Cytokine gene polymorphisms and breast cancer susceptibility L Scola, M Vaglica, A Crivello, L Palmeri, GI Forte, MC Macaluso, ... Annals of the New York Academy of Sciences 1089 (1), 104-109, 2006 | 47 | 2006 |
| Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer A Amatu, L Barault, C Moutinho, A Cassingena, K Bencardino, S Ghezzi, ... Annals of Oncology 27 (6), 1062-1067, 2016 | 39 | 2016 |
| Oxaliplatin immune-induced syndrome occurs with cumulative administration and rechallenge: single institution series and systematic review study K Bencardino, G Mauri, A Amatu, F Tosi, E Bonazzina, L Palmeri, ... Clinical Colorectal Cancer 15 (3), 213-221, 2016 | 35 | 2016 |
| Weekly docetaxel in the treatment of metastatic breast cancer L Palmeri, M Vaglica, S Palmeri Therapeutics and clinical risk management 4 (5), 1047-1059, 2008 | 35 | 2008 |
| High circulating methylated DNA is a negative predictive and prognostic marker in metastatic colorectal cancer patients treated with regorafenib A Amatu, M Schirripa, F Tosi, S Lonardi, K Bencardino, E Bonazzina, ... Frontiers in oncology 9, 622, 2019 | 34 | 2019 |
| Abstract CT005: final results of the HERACLES trial in HER2-amplified colorectal cancer S Siena, A Sartore-Bianchi, L Trusolino, C Martino, K Bencardino, ... Cancer Research 77 (13_Supplement), CT005-CT005, 2017 | 34* | 2017 |
| Should cirrhosis change our attitude towards treating non‐hepatic cancer? G Cabibbo, L Palmeri, S Palmeri, A Craxì Liver International 32 (1), 21-27, 2012 | 32 | 2012 |
| Detection and quantification of mammaglobin in the blood of breast cancer patients: can it be useful as a potential clinical marker? Preliminary results of a GOIM (Gruppo … G Gargano, V Agnese, V Calo, S Corsale, C Augello, L Bruno, L La Paglia, ... Annals of Oncology 17, vii41-vii45, 2006 | 30 | 2006 |
| Adjuvant chemotherapy of bladder cancer F Boccardo, L Palmeri Annals of Oncology 17, v129-v132, 2006 | 22 | 2006 |
